newsfilter
← Latest News
GlobeNewswire·

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2